Reaction Biology Corporation, a leading contract research organization providing early-stage drug discovery services, announced that it has launched a new division to provide ion-channel discovery services.
The EU’s CHMP adopted a positive opinion for Hemlibra (emicizumab) for routine prophylaxis of bleeding episodes in people with hemophilia A with factor VIII inhibitors.
Synergy Pharmaceuticals Inc. announced that the U.S. FDA approved Trulance (plecanatide) 3-mg tablet for the once-daily treatment of irritable bowel syndrome with constipation in adults.
June Laffey was appointed to the new position of Executive Vice President, Chief Creative Officer, McCann Health New York.
Pfizer Inc. announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera (rituximab-EU), met its primary endpoint.
McCann Health announced the appointment of Linda Szyper to the new position of Global Chief Operating Officer.
PALIO will fuse with GSW to deliver customers the best of both agencies’ integrated advertising and marketing solutions.
In this newly created role, Jennifer Gottlieb is responsible for three operating companies – W2O wcg, W2O twist and W2O pure.
The U.S. FDA granted Priority Review to daratumumab as a combination treatment for patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant.
In this white paper, PMC contends that most value assessment frameworks could unintentionally undermine the health care community’s push toward more personalized care.
